Characterization of wild-type and mutated RET proto-oncogene associated with familial medullary thyroid cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2027-2033

  Masbi, Mohammad Hosein ^a   Mohammadiasl, Javad ^a   Galehdari, Hamid ^b   Ahmadzadeh, Ahmad ^a   Tabatabaiefar, Mohammad Amin ^a   Golchin, Neda ^a   Haghpanah, Vahid ^c   Rahim, Fakher ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hereditary MTC; In silico; Inhibitor binding; Mutation; RET proto oncogene

Indexed keywords

PROTEIN RET; RET PROTEIN, HUMAN;

CARCINOMA, MEDULLARY; EXON; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MUTATION; PEDIGREE; PROSPECTIVE STUDY; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID TUMOR;

CARCINOMA, MEDULLARY; EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PEDIGREE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS;

EID: 84899044905     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2027     Document Type: Article

References (45)

1. Anders J, Kjar S, Ibanez CF (2001). Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calciumbinding site. J Biol Chem, 276, 35808-17.
2. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995). Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol, 15, 1613-9.
3. Borrello MG, Aiello A, Peissel B, et al (2011). Functional characterization of the MTC-associated germline RETK666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. Endocr Relat Cancer, 18, 519-27.
4. Bowie JU, Luthy R, Eisenberg D (1991). A method to identify protein sequences that fold into a known three-dimensional structure. Science, 253, 164-70.
5. Brady SW, Zhang J, Seok D, Wang H, Yu D (2014). Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alphaselective PI3K inhibitor. Mol Cancer Ther, 13, 60-7
6. Cheng J, Randall A, Baldi P (2006). Prediction of protein stability changes for single-site mutations using support vector machines. Proteins, 62, 1125-32.
7. Colovos C, Yeates TO (1993). Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci, 2, 1511-9.
8. Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ (2010). Virtual Screening with AutoDock: Theory and Practice. Expert Opin Drug Discov, 5, 597-60.
9. De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, et al (2013). Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab, 98, 811-9.
10. Dixit A, Torkamani A, Schork NJ, Verkhivker G (2009). Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J, 96, 858-74.
11. Eng C, Clayton D, Schuffenecker I, et al (1996). The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA, 276, 1575-9.
12. Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia, 61, 564-9.
13. Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, et al (2011). Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res, 2011, 264248.
14. Kaplan W, Littlejohn TG (2001). Swiss-PDB Viewer (Deep View). Brief Bioinform, 2, 195-7.
15. Kollman PA, Massova I, Reyes C, et al (2000). Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res, 33, 89-97.
16. Kouvaraki MA, Shapiro SE, Perrier ND, et al (2005). RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid, 15, 531-544.
17. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996). AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR, 4, 477-86.
18. Matias-Guiu X, De Lellis R (2013). medullary thyroid carcinoma: a 25-year perspective. Endocr Pathol. [Epub ahead of print].
19. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, et al (2009). Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer, 100, 1777-83.
20. Mulligan LM, Marsh DJ, Robinson BG, et al (1995). Genotypephenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med, 238, 343-6.
21. Nikiforova MN, Nikiforov YE (2008). Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn, 8, 83-95.
22. Othman NH, Omar E, Naing NN (2009). Spectrum of thyroid lesions in hospital Universiti Sains Malaysia over 11years and a review of thyroid cancers in Malaysia. Asian Pac J Cancer Prev, 10, 87-90.
23. Parthiban V, Gromiha MM, Schomburg D (2006). CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res, 34, 239-42.
24. Pinna G, Orgiana G, Riola A, Ghiani M, Lai ML, Carcassi C, et al (2007). RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/ MEN-2A phenotype. Thyroid, 17, 101-4.
25. Pronk S, Pall S, Schulz R, et al (2013). GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 29, 845-54.
26. Punales MK, Graf H, Gross JL, Maia AL (2003). RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab, 88, 2644-9.
27. Punales MK, Rocha AP, Gross JL, Maia AL (2004). [Medullary thyroid carcinoma: clinical and oncological features and treatment]. Arq Bras Endocrinol Metabol, 48, 137-46.
28. Robledo M, Gil L, Pollan M, et al (2003). Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res, 63, 1814-7.
29. Saggiorato E, Rapa I, Garino F, et al (2007). Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia. J Mol Diagn, 9, 214-9.
30. Sali A, Blundell TL (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol, 234, 779-815.
31. Santoro M, Carlomagno F, Melillo RM, Fusco A (2004). Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci, 61, 2954-64.
32. Schuffenecker I, Virally-Monod M, Brohet R, et al (1998). Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des tumeurs a calcitonine. J Clin Endocrinol Metab, 83, 487-91.
33. Schymkowitz J, Borg J, Stricher F, et al (2005). The FOLDX web server: an online force field. Nucleic Acids Res, 33, 382-8.
34. Segbena AY, Kueviakoe IM, Agbetiafa K, et al (2012). Chronic myeloid leukemia and imatinib: experience at the lome campus teaching hospital (Togo). Med Sante Trop, 22, 307-11.
35. Srinivasan J, Miller J, Kollman PA, Case DA (1998). Continuum solvent studies of the stability of RNA hairpin loops and helices. J Biomol Struct Dyn, 16, 671-82.
36. Ton GN, Banaszynski ME, Kolesar JM (2013). Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm, 70, 849-55.
37. Verkhivker GM, Bouzida D, Gehlhaar DK, et al (2003). Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. Proteins, 53, 201-19.
38. Verkhivker GM, Bouzida D, Gehlhaar DK, et al (2002). Monte Carlo simulations of the peptide recognition at the consensus binding site of the constant fragment of human immunoglobulin G: the energy landscape analysis of a hot spot at the intermolecular interface. Proteins, 48, 539-57.
39. Wang DD, Zhou W, Yan H, Wong M, Lee V (2013). Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Sci Rep, 3, 2855.
40. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004). Development and testing of a general amber force field. J Comput Chem, 25, 1157-74.
41. Wiederstein M, Sippl MJ (2007). ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res, 35, 407-10.
42. Worth CL, Preissner R, Blundell TL (2011). SDM-a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res, 39, 215-22.
43. Zedenius J, Wallin G, Hamberger B, et al (1994). Somatic and MEN 2A de novo mutations identified in the RET protooncogene by screening of sporadic MTC:s. Hum Mol Genet, 3, 1259-62.
44. Zhang Y (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9, 40.
45. Zhou Y, Zhao Y, Cui B, et al (2007). RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clin Endocrinol, 67, 570-6.